|
|
Rexahn Pharmaceuticals (RNN) |
Benzinga
Jun 17
Comment
Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stage
biopharmaceutical company developing potential best-in-class oncology
therapies, today announced that it has significantly expanded its intellectual
property around a series of novel...
StreetInsider.com
Jan 22
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Rexahn+Pharmaceuticals+%28RNN%29+Announces+New+CEO/8021159.html for the full story.
Benzinga
Dec 28
Comment
Burrill initiated coverage on Rexahn Pharmaceuticals (NYSE: RNN) with a Market Outperform rating and a $1 price target.
Burrill commented, "We believe that Rexahn's promising pipeline in oncology and CNS disorders is undervalued, and a...
Benzinga
Dec 28
Comment
Analysts at Wunderlich initiated coverage on shares of Marvell Technology Group (NASDAQ: MRVL) with a “hold” rating. Marvell's shares closed at $7.14 yesterday. Marvell's trailing-twelve-month operating margin is 10.30%.
Burrill initiated...
StreetInsider.com
Nov 29
Comment
Infoblox (NYSE: BLOX) 25% HIGHER; reported Q1 EPS of $0.06, $0.06 better than the analyst estimate of $0.00. Revenue for the quarter came in at $49.5 million versus the consensus estimate of $46.18 million. Infoblox sees FY2012 EPS of $0.17-0.21,...
StreetInsider.com
Nov 29
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Rexahn+Pharmaceuticals+%28RNN%29+Prices+Equity+Offering/7911094.html for the full story.
StreetInsider.com
Nov 28
Comment
Infoblox (NYSE: BLOX) 17% HIGHER; reported Q1 EPS of $0.06, $0.06 better than the analyst estimate of $0.00. Revenue for the quarter came in at $49.5 million versus the consensus estimate of $46.18 million. Infoblox sees FY2012 EPS of $0.17-0.21,...
StreetInsider.com
Nov 28
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Rexahn+Pharmaceuticals+%28RNN%29+To+Offer+Common+Stocks+and+Warrants/7909581.html for the full story.
StreetInsider.com
Nov 28
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Teva+Pharmaceutical+to+Provide+Additional+Funding+for+Rexahn+%28RNN%29/7907406.html for the full story.
Benzinga
Nov 21
Comment
Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stage pharmaceutical
company dedicated to developing and commercializing first-in-class oncology
therapeutics, today announced that it has been issued a United States patent
(No. 8,314,100),...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
